Compare Huntington Bancshares Incorporated (HBAN) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs Smith & Nephew plc — how do they compare? Huntington Bancshares Incorporated trades at $15.32 (market cap $31.04B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Huntington Bancshares Incorporated is far larger — about 2.8× Smith & Nephew plc's market cap, and Huntington Bancshares Incorporated pays the higher dividend (4.04%). Which is the better fit depends on your goals — on Pluang, investors hold Huntington Bancshares Incorporated for 52 Days and Smith & Nephew plc for 121 Days on average.
| HBAN | SNN | |
|---|---|---|
Market Cap | $31.04B | $11.10B |
Volume | 23,864,172 | 1,051,703 |
Sector | Financials | Health |
52-Week High | $19.27 | $37.17 |
52-Week Low | $15.02 | $26.42 |
Typical Hold Time | 52 Days | 121 Days |
Enterprise Value | $49.57B | $14.13B |
Dividend Yield | 4.04% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $15.37, up 1.32% today, but faces a bearish technical outlook with support at $15 and resistance at $16. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026, with Q3 2026 results pending. Revenue grew to $8.13B in 2025, and the stock trades at a P/E of 11.82, below the industry average, while analyst sentiment is split with a consensus price target of $19.60.
HBAN offers value with solid profitability and shareholder returns via dividends and buybacks, but near-term headwinds include interest rate pressures, margin compression, and lowered 2027 guidance. Risks involve economic sensitivity and competitive lending markets, yet institutional interest remains with significant holdings. The stock presents a cautious opportunity for value investors amid volatility.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
